Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of secondary hyperparathyroidism (iPTH \>200 pg/mL to \<500 pg/mL)~* Serum Ca \< 11.0 mg/dL, and serum P \< 7.0 mg/dL.~* At least one year of regular hemodialysis therapy~Exclusion Criteria:~* Patients with a history of hypersensitivity to any ingredient of maxacalcitol~* Patients who had received parathyroidectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.0 μg/day Alfacalcidol (Type: OTHER): Alfacalcidol 1.0 μg capsule by mouth, every day for 6 months
- 0.25 μg/day Alfacalcidol (Type: OTHER): Alfacalcidol 0.25 μg capsule by mouth, every day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).